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EXTENSIVE CLINICAL EXPERIENCE
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Context: Mutations of the gene encoding succinate dehydrogenase
subunit B (SDHB) predispose to malignant paraganglioma (PGL).
Recognition of the SDHB phenotype in apparently sporadic PGL di-
rects appropriate treatment and family screening.
Objective: The objective of the study was to assess mutation-specific
clinical and biochemical characteristics of SDHB-related PGL.
Design: The study design was retrospective descriptive.
Patients: Patients included 29 patients (16 males) with SDHB-re-
lated abdominal or thoracic PGL.
Intervention: There was no intervention.
MainOutcomeMeasures:Clinical presentations, plasmaandurine
concentrations of catecholamines andO-methylated metabolites, and
genotype-phenotype correlations were measured.
Results: Mean  SD age at diagnosis was 33.7  15.7 yr. Tumor-
related pain was among the presenting symptoms in 54% of patients
and was the sole symptom in 14%. Seventy-six percent had hyper-
tension, and 90% lacked a family history of PGL. All primary tumors
but one originated from extraadrenal locations.Mean SD tumor size
was 7.8  3.7 cm. In this referral-based study, 28% presented with
metastatic disease and all but one eventually developed metastases
after 2.7  4.1 yr. Ten percent had additional head and neck PGLs.
The biochemical phenotype was consistent with hypersecretion of
both norepinephrine and dopamine in 46%, norepinephrine only in
41%, and dopamine only in 3%. Ten percent had normal catechol-
amine (metabolite) levels, consistent with biochemically silent PGL.
No obvious genotype-phenotype correlations were identified.
Conclusions: SDHB-related PGL often presents as apparently spo-
radic PGL with symptoms related to tumor mass effect rather than
to catecholamine excess. The predominant biochemical phenotype
consists of hypersecretion of norepinephrine and/or dopamine,
whereas 10% of tumors are biochemically silent. The clinical expres-
sion of these tumors cannot be predicted by the genotype. (J Clin
Endocrinol Metab 92: 779–786, 2007)
PARAGANGLIOMAS (PGLS) are tumors that derivefrom either sympathetic tissue in adrenal and extraa-
drenal locations or parasympathetic tissue of the head and
neck (1). The majority of sympathetic tissue-derived PGLs
produce catecholamines, whereas parasympathetic PGLs
usually do not. A PGL arising from catecholamine-produc-
ing cells of the adrenal medulla is also referred to as pheo-
chromocytoma (PHEO) (2, 3). The three genes involved in the
pathogenesis of familial PGL syndrome described to date
(4–6) include those encoding the B, C, and D subunits of
mitochondrial complex II enzyme succinate dehydrogenase
(SDH). Mutations of these genes result in distinct clinical
syndromes. SDHC mutation carriers typically present with
benign solitary head and neck PGL (7), whereas SDHD mu-
tations are most frequently associated with multifocal head
and neck PGL and less frequently with adrenal and extraa-
drenal PGL (8, 9). The typical PGL associated with SDHB
mutations originates from extraadrenal abdominal or tho-
racic locations (8–11). In contrast to predominantly benign
SDHC and D-associated tumors, up to 70% of SDHB-related
abdominal and thoracic PGLs develop into metastatic dis-
ease (12).
Recognizing SDHB-related disease in individual patients
can be delayed due to several factors. Despite an autosomal
dominant pattern of inheritance, penetrance of the disease is
incomplete and age dependent (8). Many patients with
SDHB-related tumors have no family history of PGL. Of
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patients with apparently sporadic PHEO or abdominal/tho-
racic PGL, 4–7% have been identified as carriers of patho-
genic SDHB mutations (12, 13). Furthermore, the diagnosis
may be delayed by lack of symptoms related to catechol-
amine excess. Such clinically silent PGLs either do not pro-
duce catecholamines or produce and metabolize but do not
secrete catecholamines or produce dopamine but not other
catecholamines (14–17).
The aim of this study was to gain detailed insight into the
clinical and biochemical characteristics of SDHB-associated
tumors. In this single-center, referral-based study of patients
with SDHB-associated PHEO or abdominal/thoracic PGL,
clinical presentation, biochemical phenotype, tumor local-
ization and pathology, and additional diagnoses were eval-
uated for evidence of genotype-phenotype correlations.
Timely recognition of the SDHB phenotype in apparently
nonfamilial cases direct an appropriate strategy for treat-
ment, follow-up, and family screening.
Patients and Methods
Patients
This study included 29 patients (16 males, 13 females) with histo-
logical proof PHEOor of extraadrenal abdominal (including intrapelvic)
or thoracic PGL. There was no evidence of any family relationships
among patients. Eighteen patients were also included in a previous
study by our group (18). The patients represent all consecutive carriers
of an allelic variant of the SDHB gene among a large group of patients
who underwent genetic testing as part of evaluation of benign or ma-
lignant PGL at the National Institutes of Health (NIH). Genetic testing
for mutations in the SDHB gene was performed at the Department of
Human Genetics of the Pittsburgh University Medical Center as de-
scribed elsewhere (19). Patients were included between November 2000
and May 2006. The protocol for this study was approved by the Insti-
tutional Review Board of the National Institutes of Child Health and
Human Development at the NIH. All patients provided written in-
formed consent. The reason for referral to the NIH was to outline an
optimal treatment plan for (suspected) metastatic PGL. The mean  sd
interval between the initial diagnosis and referral to NIH was 5.0  8.5
yr. Clinical evaluation included a standardized inventory of symptoms
and signs. Information on individual patients is summarized in Table 1.
Laboratory tests and imaging
Blood samples were collected into heparin-containing tubes by use of
a forearm venous cannula, with patients supine for at least 20min before
sampling. Patients were instructed to fast and abstain from caffeinated
and decaffeinated beverages overnight and avoid taking acetaminophen
for 5 d before blood sampling. All samples were collected on ice, and
plasma was separated and stored at 80 C before analysis according to
recommended procedures (20). Plasma was assayed by HPLC for con-
centrations of free metanephrines and catecholamines, as described pre-
viously (21, 22), with further details and modifications as listed on the
Clinical Neurochemistry Laboratory web site (http://www.cat-
echolamine.org/labprocedures). The 24-h urinary outputs of cat-
echolamines and deconjugated (free plus conjugated) fractionatedmeta-
nephrines for patients seen at theNIHweremeasured byHPLCor liquid
chromatography with tandem mass spectroscopy, under a contract be-
tween the NIH Clinical Center and an outside commercial laboratory
(Mayo Medical Laboratories, Rochester, MN). HPLC procedures were
also used for urinary measurements in patients seen elsewhere, as de-
scribed previously. Biochemical profiles were determined during the
initial evaluation at the NIH. Hypersecretion of catecholamines was
defined as elevation of plasma and/or urine levels of the catecholamines
TABLE 1. Characteristics of individual patients
No.
Sex,
age at
diagnosis
(yr)
SDHB sequence
variant protein cDNA Ref.
Primary tumor
location,
size (cm)
Metastases,
years since
diagnosis
Metastases,
location
Family
history
of PGL
Additional diagnosis
1 F, 38 p.Pro130HisfsX5 c.391_392delC 28 l (juxta-)adrenal, 5 0.0 a/p, li, b Neg
2 M, 10 IVS1–9AG c.73–9AG 18 r paraadrenal, 10 8.4 a/p, lu, li, b, n Neg
3 F, 51 IVS31GA c.2861GA 18 r paraaortic abd, 7.5 0.9 lu, li, b Neg Hypercholesterolemia, obesity,
depression
4 M, 35 IVS3–1GC c.287–1GC New l pararenal, 14.5 0.5 a/p, li, b Pos Sinusitis, appendicitis
5 F, 34 p.Arg115X c.343CT 8, 23 bladder, 5 2.5 a/p, lu Neg
6 M, 52 p.Cys196Tyr c.587GA 8, 9 l paraaortic abd, 6.0 0.2 b Neg
7 F, 23 p.Val124SerfsX39 c.369_370insA New Paraaortic abd, 3.0 0.3 a/p, b Neg Hypothyroidism
8 F, 49 p.Ile127Ser c.380TG 18 r paraadrenal, 5.5 4.3 a/p, lu, li, n Neg
9 M, 28 p.Cys196Tyr c.587GA 8, 9, 12 Bladder/chest wall 0.0 a/p, lu, b, n Neg
10 M, 8 p.Val140Phe c.418GT 18 l parailiac art, 5.0 0.0 a/p, b Neg
11 F, 37 p.Val140Phe c.418GT 18 Pelvic, 13.5 0.8 a/p, li Neg
12 M, 10 p.Arg46X c.136CT 8, 23, 25 l paraadrenal, 5.0 17.1 a/p, lu, b, me Neg Dyspepsia
13 M, 39 p.Gln214His c.642GC 18 l paraadrenal, 9.0 4.1 a/p, lu, b, me Neg
14 F, 39 IVS32TA c.2862TA 18 l extraadrenal abd, 7.0 4.5 a/p, li, b Neg Uterus myoma, cholelithiasis
15 F, 25 p.Cys192Arg c.574TC 9, 12 r paraaortic abd, 4.0 Neg Miscarriage
16 M, 35 IVS11GT c.721GT 8, 26 Aortic bifurcation, 7.7 0.0 a/p, b, me Neg
17 M, 29 p.Gly96Asp c.287GA 18 l pararenal, 18.0 1.7 b Neg Varicocele
18 M, 60 p.Trp200Cys c.600GT New Aortic bifurcation, 6.0 0.2 a/p, lu, b Neg Cholelithiasis, deep venous
trombosis
19 M, 23 p.Arg46X c.136CT 8, 23 Aortic bifurcation, 7.5 0.0 b Neg Hiatus hernia
20 F, 24 p.Ile127Ser c.380TG 18 l juxtaadrenal, 5.5 0.0 b Neg
21 M, 47 p.Glu228GlyfsX27 c.683_684delAG 18 l para-(ad)renal, 10.0 3.5 a/p, b, me Pos Hernia nuclei pulposi,
depression
22 F, 72 IVS11GT c.721GT 8, 26 Aortic bifurcation, 10.0 0.2 a/p, b Neg Uterus myoma, hypothyroidism
23 F, 35 p.Arg46X c.136CT 8, 23 Bladder, 3.5 1.5 a/p, me Neg
24 F, 45 p.Val140Phe c.418GT 18 r paraaortic abd, 5.5 0.0 a/p Neg Uterus/bladder prolaps,
cholelithiasis
25 F, 51 IVS5–2AG c.541–2AG 18 r adrenal, 5.5 3.4 a/p, me, n Pos Benign breast tumor, colon
polyps, melanoma, goiter
26 M, 11 p.Val140Phe c.418GT 18 Paraaortic abd, 8.0 1.1 a/p, lu, b Neg Myocardial hypertrophy, hernia
nuclei pulposi
27 M, 39 p.Arg46Gln c.137GA 27 l extraadrenal abd, 15.0 0.0 a/p, me, b Neg
28 M, 7 p.Arg230His c.689GA 10 l pararenal, 4.0 7.1 a/p, lu, b Neg
29 M, 35 p.Val140Phe c.418GT 18 l pararenal, 8.0 13.3 b Neg Asthma, acid reflux, nodule l
upper thyroid
Pos, Positive; Neg, negative; M, male; F, female; l, left; r, right; art, artery; abd, abdomen; a/p, abdominal/pelvic; lu, lung; li, liver; me,
mediastinum; n, neck.
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and/or the O-methylated metabolites metanephrine and normetaneph-
rine above the upper range of normal.
Anatomic localization of PGL was performed by whole-body CT
and/or whole-body MRI, which included the head and neck area in
search of (additional) parasympathetic PGL.
Results
Initial clinical presentation
Age at presentation of first symptoms was 30.6  16.0
(range 6–70) yr. The initial clinical presentation included
one or more symptoms relating to catecholamine excess in
23 of 28 (82%) of patients (Table 2). Nine of 28 (32%)
patients had a classic triad of headache, palpitations and
diaphoresis. These symptoms occurred episodically in 14
of 16 (88%) patients, were related to exercise in three
patients (no. 5, 20, and 26) and to micturition in two
patients (no. 10, 24). The latter two had intrapelvic tumors.
Three patients presented with hypertensive crisis, either
during pregnancy (no. 5) or during anesthesia for stomach
surgery (no. 19), one coinciding with stroke (no. 28). Twen-
ty-two of 29 (76%) patients had a history of hypertension,
including one (no. 1) who became blind due to hyperten-
sive retinopathy.
Tumor-related pain was among the initial presenting
symptoms in 15 of 28 (54%) patients, and was the sole pre-
senting symptom in 4 patients (no. 17, 18, 21, 27). One of these
patients (no. 17) presentedwith upper abdominal discomfort
caused by a large 18 cm retroperitoneal mass. Another (no.
18) had experienced pelvic pain, hematuria and weight loss
before presentingwith deep venous thrombosis of the left leg
due to intrapelvic metastases. Another (no. 27) presented
with back pain related to multiple metastatic lesions of the
lumbar spine that were pathologically proven to be metas-
tases of a large, 16 cm extra-adrenal PGL located in the left
retroperitoneum. These 3 patients lacked symptoms of cat-
echolamine excess, which is consistent with the findings of
normal levels of plasma and urine catecholamines and cat-
echolamine metabolites. Also, during progression of meta-
static lesions during follow-up, their plasma and urine levels
of catecholamines and their metabolites remained normal.
The fourth patient (no. 21) who had pain as an isolated initial
symptom presented with abdominal pain and nausea due to
an invasive 10 cm retroperitoneal tumor. Laboratory findings
in this particular patient indicated isolated hypersecretion of
dopamine and not of other catecholamines. Later on he de-
veloped metastatic lesions to the bone and mediastinum. At
this point he did experience occasional palpitations, dia-
phoresis and bouts of hypertension in addition to therapy-
resistant bone pain. Another patient (no. 11) was completely
free of symptoms and signs, when a 9-cm intrapelvic tumor
was incidentally discovered on ultrasound during preg-
nancy. Her laboratory findings were consistent with both
norepinephrine and dopamine production.
In 3 of 29 (10%) patients, family history was positive for
PGL. The father of one patient (no. 4)was a carrier of the same
SDHBmutation as was his son (IVS3–1GC), and had a neck
PGL removed at age 30. The father of another patient (no. 21)
had multiple head and neck PGL and was being treated for
malignant abdominal PGL with multiple bone lesions else-
where. The mother of another patient (no. 25) had a medi-
astinal PGL removed in her fifties and was doing well. In-
formation on the genotype of the latter two relatives is
lacking. A sister of another (no. 23), who was also carrier of
the p.Arg46X mutation, had no history of PGL, but was
treated for papillary thyroid cancer.
TABLE 2. Signs and symptoms at presentation
Patient no. Head-ache
Tachycardia/
palpitations Diaphoresis Flushing Pallor Tremor
Anxiety/
panic
attacks
Hyper-
tension Dizziness Nausea
Chest
pain
Tumor-
related
pain
Additional
comments
1         Severe hypertensive retinopathy, fatigue
2     
3            
4           Recent diabetes mellitus, weight loss
5            Exercise-related symptoms, hypertensive crisis
during pregnancy
6             Weight loss
7            Constipation, dyspnea
8        Fatigue
9             Tachycardia upon voiding, fatigue, weight loss
10   
11             No symptoms (incidentaloma on ultrasound
for pregnancy)
12         Fatigue
13  Presenting symptoms unknown, patient diseased
14    
15             Fatigue, orthostatic tachycardia, dizziness
16           Erectile dysfunction, deep venous thrombosis,
weight loss
17         Fatigue, dyspnea
18            Deep venous trombosis, hematuria, fatigue,
weight loss
19       Fatigue, weakness
20            Exercise-related nausea/vomiting, abdominal pain
21        
22        Fatigue, weight loss, blurred vision, constipation,
weakness
23       Sympoms related to voiding
24       Dizziness
25             Dyspnea
26            Exercise-related symptoms, fatigue, weakness
27            
28             Hypertensive crisis including stroke
29             Numbness in hands, fatigue
Percent
of total
62 68 56 44 20 29 62 75 32 57 53 54
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Diagnosis and follow-up
Mean  sd age at diagnosis of PHEO or PGL was 33.7 
15.7 yr. The delay until the diagnosis was 4.5  4.6 (range
1–19) years. Primary tumors, detected by either computed
tomography (CT) or magnetic resonance imaging (MRI),
were in extraadrenal locations in all but one patient (no. 25).
The maximal diameter of the primary tumors from either
pathology or radiology reports was 7.8  3.7 cm. In eight of
29 (28%) patients, metastatic disease was already apparent at
initial presentation. Malignant PHEO and PGL was defined
as the presence of metastatic lesions at sites in which chro-
maffin tissue is normally absent (23). Pathology reports of all
resected (n  21) and biopsied (n  8) primary tumors were
consistent with PHEO or PGL. In 14 of 29 (48%) patients,
tumor invasion of blood/lymphatic vessels or adjacent or-
gans was mentioned in the pathology report. Head and neck
PGLs had been diagnosed before referral in three of 2930
(10%) patients (no. 12, 21: left glomus caroticum, and no. 24:
left glomus jugulare). No additional head and neck tumors
were identified during evaluation at the NIH. Additional
diagnoses from medical history are indicated in Table 1.
In this referral-based study, all patients except one devel-
oped metastatic lesions. One patient (no. 15) had no radio-
logical or biochemical evidence of malignant PGL. Mean
interval between diagnosis of PGL and metastatic disease
was 2.7  4.1 (range 0–17) yr. Metastatic locations included
the abdominal/intrapelvic compartment (outside the liver)
in 89% of patients, bone in 75%, lung in 36%, liver in 25%,
mediastinum in 29%, and head or neck in 14% (Table 1).
Metastatic lesions were detected by CT and/or MRI in 27 of
28 (96%) patients. In one patient (no. 20), CT and MRI were
negative, whereas [123I]-metaiodobenzylguanidine scintigra-
phy showed multiple bone lesions as well as pathological
activity in the right abdominal paraaortic region. Four pa-
tients died of widespread metastatic disease (no. 8, 13, 22,
and 25).
Biochemical phenotype
Data available from outside centers on laboratory findings
at diagnosis of primary nonmetastatic PHEO were limited.
At diagnosis of the primary tumor, plasma concentrations of
norepinephrine were elevated in five of five patients, free
normetanephrine in five of six, and plasma dopamine in
three of six, whereas none had elevated plasma concentra-
tions of epinephrine or free metanephrine. At this point, 24-h
urinary output of norepinephrine was elevated in six of
seven patients, deconjugated normetanephrine in four of six,
vanillylmandelic acid in nine of 10, dopamine in one of one,
and epinephrine andmetanephrine in none. At evaluation of
metastatic disease at the NIH, the profile of catecholamine
hypersecretion was distributed as follows: both norepineph-
rine and dopamine in 13, norepinephrine only in 12, dopa-
mine only in one, and no hypersecretion of catecholamines
in the three (Table 3). Two patients (no. 9, 22) with wide-
TABLE 3. Biochemical phenotype
Plasma Urine
Biochemical phenotype
Patient no. NE E DA NMN MN CgA NE E DA NMN MN
1          NEDA
2            NEDA
3         NE
4            NEDA
5           NE
6           NE
7           NE
8           NEDA
9           NEDA (E)
10           NEDA
11           NEDA
12           NEDA
13          NEDA
14           NE
15      NE
16            NEDA
17         none
18            none
19           NEDA
20            NE
21            DA
22      NEDA (E)
23            NEDA
24            NE
25            NE
26           NE
27            none
28            NE
29       NE
Percent of total 86 3 48 82 7 81 75 0 33 84 20
Elevated (marked as) and normal (marked as) concentrations of catecholamines and theirmetabolites at evaluation ofmetastatic disease
(all but no. 16) and primary nonmetastatic PHEO (no. 16). Patients 8 and 14 were evaluated after chemotherapy. NE, Norepinephrine; E,
epinephrine; DA, dopamine; NMN, normetanephrine; MN, metanephrine; CgA, chromogranin A.
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spreadmetastatic disease from extraadrenal PGL and largely
elevated levels of norepinephrine and dopamine had addi-
tional elevation of plasma epinephrine and/or metaneph-
rine. In the first patient (no. 9), plasma norepinephrine and
dopamine were increased to 55 and 4 times the upper ref-
erence limit of normal, respectively, whereas plasma epi-
nephrine was normal and plasma metanephrine was ele-
vated to twice the upper limit, respectively. The second
patient (no. 22) with largely increased plasma norepineph-
rine (40 times the upper limit) and dopamine (25 times the
upper limit) also had mildly elevated plasma levels of epi-
nephrine andmetanephrine (both two times the upper limit)
on one occasion. Plasma concentrations of chromogranin A
were elevated in 13 of 16 patients (81%) and 10 of 13 patients
(77%) with metastatic disease (Table 3).
Genotype-phenotype correlation
In 29 index patients, 20 different sequence variants of the
SDHB gene were found (Table 1), nine of which had been
previously reported as disease-causing mutations by others
(8, 9, 12, 13, 24–29). Eleven allelic variants were identified by
our group, eight of whichwere published previously (18). Of
these 11 variants, nine are very likely to represent disease-
causing mutations for the following reasons: five were also
found in other patients with PGL (no. 4, 8, 11, 14, 18, 20, 24,
26, 29), two resulted in a frameshift causing a premature stop
codon and a truncated protein (no. 7, 21), one was located in
a splice site donor site (no. 3), and one in a splice site acceptor
site (no. 25). The latter two splice site mutations are likely to
interfere with RNA processing. In addition, the p.Val140Phe
allelic variant, which was present in five patients (Table 1),
was absent in 100 control subjects. Whether the missense
mutations observed in the remaining two patients (no. 2 and
13) with new variants represent disease-causing mutations
remains to be confirmed. In the first patient (no. 2) the variant
was located close to a splice acceptor consensus region,
whereas the variant in second patient (no. 13) causes sub-
stitution of an amino acid in a strongly conserved region of
the protein. Family history of both patients was negative for
PGL. Additional genetic testing for additional mutations of
SDHD, RET, and VHL genes was performed in 21, 20, and 19
patients, respectively. All results were negative.
Genotype-phenotype correlations among patients with
SDHB mutations in different exons did not reveal obvious
differences for age at presentation, biochemical phenotype,
primary tumor size and location, distribution of metastatic
lesions, or presence of additional head and neck PGLs (Fig.
1).
Discussion
Important information on the clinical characteristics and
penetrance of different SDH-related PGL syndromes among
index cases and their family members was gathered by large
multinational PGL study consortia (8, 9, 12). In these reports,
a particularly severe clinical phenotype of tumors with high
malignant potential was observed in carriers of a mutation
in the SDHB gene. We present the first single-center evalu-
ation of genetic, clinical, and biochemical characteristics of a
large group of patients with SDHB-related PGL. Early rec-
ognition of features pointing toward SDHB-related disease is
important because this diagnosis warrants aggressive ther-
apy and intensive follow-up.
Clinical presentation
The majority of patients had one or more symptoms re-
lated to catecholamine excess in addition to hypertension.
However, only one third had the classical triad of headache,
palpitations, and diaphoresis. In more than half of the pa-
tients, the clinical picture at initial presentation was domi-
nated by problems caused by space-occupying effects of the
tumor, including pain or discomfort, deep venous throm-
bosis, urological problems, andweight loss. These symptoms
and signs are unusual in benign PHEO and PGL and prob-
ably relate to a high prevalence of large invasive tumors and
metastatic disease at presentation. Space-occupying compli-
cations in patients with suspected PGL should trigger clini-
cians to think of an SDHB-relatedmalignant tumor. An atyp-
ical presentation may account for the observed mean delay
between the onset of symptoms and the diagnosis of 4.5 yr.
The majority of the currently investigated patients pre-
sented in their early 30s, which is similar to earlier obser-
vations for index cases (8).We confirm, however, that SDHB-
related tumors may also occur in young children before 10
yr of age or not until after age 65 yr (11, 27). The age-related
penetrance among SDHB mutation carriers was found to be
29% by 30 yr of age and 45% by age 40 yr (8). Genetic and/or
environmental factors responsible for this large variability in
penetrance are unknown.
Only 10% of the currently investigated patients had a
family history of PGL, compared with 37% of patients in a
previous report (8). In the same study, screening of asymp-
tomatic SDHB-positive relatives identified tumors in 11% (8).
We agree with the notion that all first-degree family mem-
bers of patientswith SDHB-associated PGL should be offered
genetic testing (30). We are currently extending our genetic,
clinical, and biochemical studies to the patients’ relatives.
Our findings emphasize that a negative family history of
PHEO and PGL by no means rules out the presence of an
SDHB mutation. The prevalence of SDHB mutations in ap-
parently sporadic nonsyndromic PHEO is 4–7% (12, 13, 31).
It is in the patients lacking a positive family history that
clinicians depend on other clinical, biochemical, and radio-
logical clues for SDHB mutations. Familial PGL syndrome
may be expected from the finding of additional head and
neck PGL, which are present in up to 31% of SDHBmutation
carriers (8, 9). In addition, 80% of SDHB-associated PGL are
located in extraadrenal abdominal, intrapelvic, or thoracic
locations (12). Tumors are more often multifocal and are
usually large,with diameters of around 9 cm (12). Among the
patients in the current study, only 10% had an additional
head or neck PGL and asmany as 97% of the primary tumors
were in extra-adrenal locations, with a mean diameter of
nearly 8 cm.
Biochemical phenotype
Evaluation of the biochemical phenotype of PGL mainly
revealed hypersecretion of norepinephrine and/or dopa-
mine. Our findings of predominant hypersecretion of nor-
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epinephrine are consistent with the notion that extraadrenal
PGL rarely secrete epinephrine (32). This probably reflects a
decreased expression of phenylethanolamine-N-methyl-
transferase, the enzyme that converts norepinephrine to epi-
nephrine (33). According to limited information on the bio-
chemical phenotype of SDHB-related PGL in a previous
report (8), six of 30 patients showed elevated urinary excre-
tion of both epinephrine and norepinephrine, whereas one of
30 patients showed elevations confined to urinary epineph-
rine. It is not mentioned whether elevated urinary epineph-
rine levels were found in adrenal or extraadrenal tumors.
Cosecretion of dopamine, which was present in half of the
patients with norepinephrine hypersecretion, is mainly
found in multifocal or metastatic extraadrenal PGL (14). In
addition, increased excretion of dopamine was shown to
predict malignant potential in preoperative patients with
apparently nonmetastatic PGL (34). Exclusive overproduc-
tion of dopamine, as found in one patient, is rare and mainly
occurs in extraadrenal PGL (14, 16, 17). As observed in the
case we present here, these patients have an atypical pre-
sentation, lacking symptoms of catecholamine excess and
hypertension (16). In clinical practice, measurement of
plasma levels of dopamine or its O-methylated metabolite
methoxytyramine should be considered for identification of
tumors that predominantly produce dopamine but only in
patients with an atypical presentation in whom PGL is
strongly suspected despite normal plasma and urinary levels
of other catecholamines, and the catecholamine O-methyl-
ated metabolites, normetanephrine, and metanephrine (14).
Patients with PGL who lack symptoms of catecholamine
excess pose a significant diagnostic challenge (15). Such clin-
ically silent tumors may occur in PGLs that do not produce
catecholamines, in those that produce andmetabolize, but do
not secrete catecholamines, and those that produce dopa-
mine but not other catecholamines (14–16). The diagnosis of
biochemically silent tumors, i.e. tumors that either do not
FIG. 1. Phenotype of index patients with PHEO according to SDHB mutation. The eight exons of SDHB are represented diagrammatically.
Missense mutations are shown in the upper portion of the figure, and truncating or splice site mutations are shown in the lower portion. The
phenotype observed in each patient is represented by a unit of four boxes, with the patient number shown above. DA producing, Hypersecretion
of dopamine ( other catecholamines).
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produce or do not secrete catecholamines, is usually delayed
until advanced metastatic disease, when complications of
space-occupying lesions occur. This was also the case in the
three patients with biochemically silent tumors in the current
study. In this respect, these SDHB-related extraadrenal ab-
dominal PGLs appear to share features with parasympa-
thetic head and neck PGLs, which are also usually biochem-
ically silent (35). These tumorsmay arise from subsets of cells
that lack the ability to produce, metabolize, and secrete cat-
echolamines. Alternatively, tumor cells may lose this ability
due to dedifferentiation before the tumor is big enough to
secrete significant amounts of catecholamines. For the mon-
itoring of these biochemically silent PGLs, plasma levels of
chromogranin A may provide an alternative biochemical
parameter (36). Plasma chromogranin was positive in two of
the three patients’ tumors that did not produce
catecholamines.
SDHB mutations and malignant disease
Of the patients described in our study, all but one (97%)
developedmetastatic lesions of PGL at a mean interval of 2.7
yr after the diagnosis. The finding of a very high rate of
malignant PGL among SDHB mutation carriers is due to
selection bias of this referral-based study. In the majority of
cases, the actual reason for referral to theNIHwas evaluation
and treatment of metastatic disease. However, among pre-
viously described patients with SDHB-associated PHEO or
abdominal/thoracic PGL, the rates of malignancy were also
high: 11 of 32 (34%) (9), 15 of 21 (71%) (12), and 18 of 48
(37.5%) (8). In nearly one third of cases, though, malignant
diseasewas already evident at the initial diagnosis of PHEO/
PGL, which is similar to the previous finding of 22% (8).
Apart from malignant PGL, SDHB mutations have been
suggested to be associated with malignant tumors of the
extraparaganglial system. Among 53 SDHB mutation carri-
ers, two patients from the same family had renal clear cell
carcinoma at young age and one patient with a different
mutation had a papillary thyroid carcinoma at age 14 yr (9,
37). These associations, however, were not confirmed by
more recent studies (8, 12) including the present one.
Previously, genotype-phenotype correlations failed to dis-
tinguish differences in tumor location and malignant po-
tency of SDHB-related PGL between different mutations (8).
In addition, clinical phenotypes may largely differ between
family members with the same mutation. In the present
study, features that are associated with aggressive tumor
behavior, including young age at presentation, large tumor
size, metastatic disease at presentation, and hypersecretion
of dopamine, were equally distributed among patients with
missense vs. truncating mutations and were independent of
exon locations.
Apart from intragenic mutations, there are two reports on
five patients with extraadrenal PGL related to large deletions
of the SDHB gene (38, 39). These whole gene or partial de-
letions, with a possible hot spot in the first exon, remain
undetected by conventional SDHB gene analysis. Because
data on such deletion families are still limited, it remains to
be elucidated whether this genotype is associated with a
phenotype distinct from intragenic SDHB mutations.
Conclusions
SDHB-associated PHEO and PGL is characterized by a
high malignant potency, warranting aggressive therapy,
strict follow-up, and family screening. The diagnosis may be
delayed by a negative family history and an atypical clinical
presentation with signs and symptoms that are predomi-
nantly related to tumor growth rather than to catecholamine
excess. The biochemical phenotype usually consists of hy-
persecretion of norepinephrine and/or dopamine, but 10%
of tumors are biochemically silent. The clinical expression of
these tumors in individual patients cannot be predicted by
the type and location of the SDHB gene mutation.
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